BPC-157: Peptide for Gut Healing, Tendon Repair & Tissue Recovery
60-Second Summary
BPC-157, also known as Body Protection Compound 157, is a synthetic peptide derived from a protective protein found in gastric juice. Preliminary research suggests it may support gut barrier integrity, accelerate tendon and muscle healing, and promote tissue repair through multiple biological pathways. Evidence is primarily from animal and cell culture studies; human clinical trials remain limited. While generally well-tolerated in research settings, long-term safety data in humans is incomplete, and supplemental BPC-157 remains largely unregulated.
What is BPC-157?
BPC-157 is a 15-amino-acid synthetic peptide sequence derived from Body Protection Compound, a naturally occurring peptide found in gastric juice and other body fluids. It is classified as a specialty peptide and is not approved as a pharmaceutical drug in most jurisdictions, existing primarily in the research and supplement marketplace.
BPC-157 is thought to work through multiple mechanisms, including stimulation of growth factor pathways (particularly vascular endothelial growth factor and hepatocyte growth factor), modulation of nitric oxide production, and promotion of angiogenesis (new blood vessel formation). It also appears to interact with dopamine and serotonin signaling, which may explain some of its reported neuroprotective effects.
As an oral peptide, BPC-157 faces significant absorption challenges; it is a polypeptide and therefore subject to degradation by digestive enzymes and low bioavailability through the gastrointestinal tract. Most published research has used parenteral (injection-based) administration, raising questions about the efficacy of oral supplemental forms commonly marketed to consumers.
Evidence-based benefits of BPC-157
BPC-157 has attracted interest from athletes, fitness enthusiasts, and individuals seeking to accelerate tissue repair, though the evidence base is still developing. Most research has been conducted in animal models and cell culture; robust human clinical trials are sparse. The following areas have been the focus of preliminary investigation:
Gut Barrier Support and GI Healing
Animal studies and some preliminary human case reports suggest BPC-157 may promote healing of the intestinal epithelium, potentially supporting recovery from gastric ulcers and inflammatory gut conditions. The proposed mechanism involves enhanced tight junction function and increased blood flow to the digestive tract. However, human evidence remains limited to anecdotal reports and very small open-label studies.
Tendon and Ligament Repair
Rat and mouse models demonstrate accelerated healing of damaged tendons and ligaments when BPC-157 is administered, often surpassing standard treatments. A small number of human case studies report subjective improvement in tendon injuries, but no large-scale randomized controlled trials in humans have yet been published. Athletes and orthopedic practitioners interested in this peptide should consider the evidence preliminary.
Muscle Recovery and Wound Healing
Preclinical research indicates BPC-157 may enhance muscle regeneration after injury and accelerate skin wound closure via promotion of angiogenesis and fibroblast activation. Early-stage human reports are encouraging, but robust clinical evidence is lacking. Time to onset and optimal dosing in humans remain undefined.
Neuroprotection and Nerve Recovery
Cell culture and animal studies show BPC-157 protects neurons from excitotoxicity and may support peripheral nerve regeneration. Some preliminary reports suggest potential benefit for nerve injuries, though clinical validation in humans is absent. This area remains highly speculative for human supplementation.
Dopamine and Mood Modulation
Animal models indicate BPC-157 influences dopaminergic and serotonergic pathways, with some studies suggesting anxiolytic and mood-supporting properties. Human evidence is nonexistent; any mood-related claims in marketing materials should be viewed with considerable skepticism.
Supplement forms of BPC-157, compared
BPC-157 is available primarily as an injectable peptide (subcutaneous or intramuscular injection) sold through research chemical suppliers and some specialized supplement retailers. Oral capsule and powder forms are also marketed, though oral bioavailability is severely limited due to digestive enzyme degradation. No established oral formulation has undergone robust pharmacokinetic study in humans.
How much BPC-157 should you take?
There is no established recommended daily intake or official dosage guideline for BPC-157 in humans, as it is not an approved pharmaceutical and clinical data are sparse. Most published animal research has employed doses in the range of 10–100 mcg/kg body weight, often administered via injection. Human case reports and supplement labels typically suggest 200–500 mcg per dose, though the basis for these recommendations is unclear.
- Typical research protocol: 10–100 mcg/kg body weight, often via subcutaneous injection, once or twice daily.
- Common oral supplement dose: 200–500 mcg, 1–2 times daily (though absorption may be minimal).
- Injection protocol: Some practitioners administer 100–250 mcg subcutaneously once daily or every other day.
- Duration: Most animal studies lasted 14–90 days; optimal duration in humans is unknown.
There is no pharmacokinetic data establishing whether BPC-157 should be taken with or without food, whether oral absorption is improved by any particular delivery method, or whether tolerance develops with long-term use. Anyone considering BPC-157 supplementation should consult a healthcare provider familiar with peptide therapeutics, as dosing, administration route, and duration remain highly individualized and experimental in human contexts.
Safety, side effects, and risks
BPC-157 has a relatively benign safety profile in animal models and in anecdotal human reports, with no severe toxicity or lethality observed even at very high doses. However, long-term safety data in humans are limited, and no large-scale adverse event surveillance has been conducted. Regulatory oversight is minimal to absent in most countries.
Common Side Effects
Most published animal studies report no overt adverse effects. Anecdotal human reports occasionally mention mild injection site irritation (redness, soreness) when administered via subcutaneous injection, and rare reports of transient mild gastrointestinal symptoms (nausea, bloating) with oral forms. These are not well-quantified and may reflect individual variability or nocebo effects.
Pregnancy and Lactation
There are no human safety data for BPC-157 in pregnancy or lactation. Because it is a synthetic peptide with uncharacterized effects on fetal development or milk composition, supplementation during pregnancy or breastfeeding is not recommended pending further research.
Drug and Supplement Interactions
No formal interaction studies exist. Because BPC-157 is proposed to modulate growth factors, nitric oxide, and monoamine neurotransmitters, theoretical interactions with vasodilators, anticoagulants, antidepressants, and immunosuppressants are plausible but unconfirmed. Blood pressure monitoring may be prudent if combining BPC-157 with agents that affect vascular tone.
Important Safety Caveat
BPC-157 products sold as supplements are not FDA-approved and are not manufactured under pharmaceutical-grade standards in most cases. Batch purity, sterility, and contaminant testing are often absent. Before using BPC-157, consult a physician, particularly if you have a bleeding disorder, are on anticoagulant or antiplatelet therapy, are pregnant or nursing, or have a history of autoimmune or inflammatory conditions. Do not self-treat serious injuries or infections with BPC-157 alone.
Drug and nutrient interactions
- Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel): BPC-157 may enhance nitric oxide signaling and vascular permeability; concurrent use could theoretically increase bleeding risk, though no clinical evidence exists. Monitoring is warranted.
- Antihypertensive medications: BPC-157's effects on vasodilation and blood pressure are unclear; combining with blood pressure-lowering drugs may require dose adjustment and clinical oversight.
- SSRIs and other serotonergic agents (sertraline, fluoxetine): BPC-157 appears to modulate serotonin pathways; concurrent use is theoretically possible but unvalidated and may alter mood or neurological effects.
- Growth factor antagonists or immunosuppressants: BPC-157's mechanism involves growth factor promotion; use alongside immunosuppressive therapies may require medical supervision.
- NSAIDs (ibuprofen, naproxen): Some preliminary data suggest BPC-157 may enhance healing; combined use for injury recovery is speculative and unproven in humans.
Given the limited human data, any combination of BPC-157 with other supplements or medications warrants discussion with a healthcare provider. Use our interaction checker tool to cross-reference specific agents, and always disclose BPC-157 use to your clinician.
Who might benefit — and who shouldn't self-supplement without guidance
| Most likely to benefit from supplementing | Use with caution or seek medical guidance first |
|---|---|
| Athletes recovering from acute tendon or ligament injuries (evidence remains preliminary) | Individuals on anticoagulants or with a history of bleeding disorders |
| Those with inflammatory or erosive gut conditions seeking adjunctive support (under medical supervision) | Pregnant or lactating individuals (no safety data) |
| People with slow-healing wounds or chronic tissue damage interested in experimental approaches | Patients with autoimmune or inflammatory conditions without medical oversight |
| Individuals curious about peptide therapeutics and willing to accept experimental status | Those taking monoamine oxidase inhibitors, SSRIs, or other serotonergic drugs without consulting their clinician |
| Healthy adults with minor acute injuries exploring research-backed but unproven options | Individuals with renal or hepatic impairment (peptide metabolism not established) |
Frequently asked questions
Is BPC-157 legal and FDA-approved?
BPC-157 is not FDA-approved as a pharmaceutical drug in the United States. It is sold as a research chemical or dietary supplement, largely unregulated and not subject to the same manufacturing or safety standards as approved drugs. Legal status varies by country and jurisdiction. Always check your local regulations before purchasing.
What is the difference between injectable and oral BPC-157?
Most published research uses injectable (subcutaneous or intramuscular) administration, which bypasses digestive enzyme degradation. Oral forms have very poor bioavailability because BPC-157 is a peptide vulnerable to stomach acid and proteolytic enzymes. Oral capsules and powders are marketed, but their efficacy is unproven and likely minimal compared to injection.
How long does it take to see results from BPC-157?
There is no human data on time to onset. Animal studies show tissue changes over 2–4 weeks, but human healing timelines are undefined. Anecdotal reports vary widely from days to months. Expectations should be cautious, and BPC-157 should not replace standard medical care for serious injuries.
Can I stack BPC-157 with other supplements or peptides?
Stacking BPC-157 with other growth-factor-promoting peptides (such as TB-500 or ipamorelin) or with supplements like collagen peptides is done anecdotally but unvalidated in humans. Combining with NSAIDs or other pain relievers is common among athletes, but synergistic effects are unknown. Consult a healthcare provider before combining.
Is BPC-157 safe for long-term use?
Long-term safety in humans has not been formally studied. Animal models show good tolerability over weeks to months, but chronic use lasting years has not been examined. Until human clinical trials are completed, long-term safety should be considered unestablished.
Does BPC-157 have any nootropic or mood-boosting effects?
Animal studies suggest BPC-157 influences dopamine and serotonin pathways, but there is no human evidence of mood enhancement, anxiety reduction, or cognitive benefits. Marketing claims about mood or mental health should be viewed skeptically until clinical data emerge.
What should I do if I experience side effects from BPC-157?
Most users report no side effects, but if you experience injection site reactions, gastrointestinal discomfort, dizziness, or mood changes, discontinue use and consult a healthcare provider. Because BPC-157 affects growth factors and blood vessels, any signs of unusual bleeding, bruising, or swelling warrant immediate medical attention.
Related ingredients
Collagen Peptides
Related ingredient — see the Collagen Peptides reference page.
Bone Broth Protein
Related ingredient — see the Bone Broth Protein reference page.
Bcaa
Related ingredient — see the Bcaa reference page.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.